ReNerve Delivers Strong Sales Momentum and Advances Nerve Repair Pipeline
ReNerve Limited (ASX: RNV) reported a strong quarterly performance, driven by accelerating sales and continued progress across its medical device portfolio. Sales increased by 79% compared to the same period last year, with March marking the company’s first month exceeding AU$100,000 in revenue, highlighting growing market adoption of its products.
The company expanded its international footprint by securing regulatory approvals for its NervAlign Nerve Cuff in Malaysia and Hong Kong, strengthening its position in the Asia-Pacific region. In product development, the NervAlign Nerve Guide Matrix advanced to Stage 3, representing a key milestone toward regulatory submission and future commercialisation.
From a financial perspective, ReNerve maintained a stable position with a closing cash balance of AU$3.32 million, supported by funding inflows and an R&D tax incentive. Overall, the company is building momentum through rising sales, innovation, and global expansion.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
ReNerve Delivers Strong Sales Momentum and Advances Nerve Repair Pipeline
ReNerve Limited (ASX: RNV) reported a strong quarterly performance, driven by accelerating sales and continued progress across its medical device portfolio. Sales increased by 79% compared to the same period last year, with March marking the company’s first month exceeding AU$100,000 in revenue, highlighting growing market adoption of its products.
The company expanded its international footprint by securing regulatory approvals for its NervAlign Nerve Cuff in Malaysia and Hong Kong, strengthening its position in the Asia-Pacific region. In product development, the NervAlign Nerve Guide Matrix advanced to Stage 3, representing a key milestone toward regulatory submission and future commercialisation.
From a financial perspective, ReNerve maintained a stable position with a closing cash balance of AU$3.32 million, supported by funding inflows and an R&D tax incentive. Overall, the company is building momentum through rising sales, innovation, and global expansion.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au